nombre del producto:vapreotida,Octastatina,vapreotida
Secuencia: D-Phe-[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp-NH2
Alias:Sanvar,RC-160;VAPREOTIDA;D-PHE-CYS-TYR-D-TRP-LYS-VAL-CYS-TRP-NH2; Octastatina;
FCYWKVCW-NH2;D-Phe-L-Cys(1)-L-Tyr-D-Trp-L-Lys-L-Val-L-Cys(1)-L-Trp-NH2;
No CAS.: 103222-11-3
Fórmula molecular: C57H70N12O9S2
Peso molecular: 1131.40
Pureza (HPLC): 98.0%
Apariencia: polvo blanco
impureza única(HPLC): 1.0%
Composición de aminoácidos: 10% de teoría
Contenido de péptidos(NORTE%): 80%(por %N)
Contenido de agua(karl fischer): 6.0%
Contenido de acetato(HPIC): 15.0%
Balance de masa: 95.0~105,0%
Calificación : Grado farmacéutico
Almacenamiento: Cerrado, abajo 2 ~ 8 ℃ preservación
Uso : El fármaco se puede utilizar para el tratamiento de la hemorragia por várices esofágicas agudas tempranas. (EVB) y terapia intervencionista endoscópica antes de la hemostasia, también puede estar sangrando dentro 5 d lente para el tratamiento y la prevención de la recurrencia después de la endoscopia. El acetato de vapreotida será el único tratamiento aprobado para el sangrado por várices esofágicas en los Estados Unidos..
Variceal bleeding is a life-threatening complication of portal hypertension. The recommended treatment includes the early administration of a vasoactive drug. Vapreotide is a somatostatin analogue with a different receptor affinity to octreotide. It decreases portal pressure and blood flow of collateral circulation in rats with cirrhosis. The pivotal study of early administration of vapreotide in patients with cirrhosis and variceal bleeding has shown a significant improvement in bleeding control and, in the subset of patients with significant bleeding, a significant reduction in mortality. Además, a meta-analysis of four randomized studies has shown a significant improvement in bleeding control. Vapreotide administrated via the intravenous route is simple to use, with practically no contraindications and few, usually minor, side effects.
The immediate release formulation of Sanvar, a somatostatin analogue, is used in the treatment of acute esophageal variceal bleeding (EVB).Sanvar is used prior to endoscopic intervention to control haemorrhage and prevent re-bleeding during the critical five days following the onset of bleeding. EVB is a life threatening condition and the mortality rate is high (about 15% a 25%) in the first six weeks following the haemorrhage. EVB is the cause of about 70% of gastro-intestinal bleeding in patients suffering from liver cirrhosis.
